KLK3 and prostate carcinoma: In this randomized clinical trial of 12 743 men with no previous prostate cancer diagnosis, a blood-based biomarker (Stockholm3 risk score ≥0.15) combined with systematic biopsies detected clinically significant prostate cancer at levels comparable with MRI-targeted biopsies based on PSA levels.